01 17Xarelto
02 2Xarelto
03 1XareltoTM
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 5,461
2019 Revenue in Millions : 4,991
Growth (%) : 9
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 2,345
2019 Revenue in Millions : 2,313
Growth (%) : 1
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 5,213
2020 Revenue in Millions : 5,461
Growth (%) : 5
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 2,438
2020 Revenue in Millions : 2,345
Growth (%) : 4
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 4,742
2021 Revenue in Millions : 5,213
Growth (%) : -9
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 2,473
2021 Revenue in Millions : 2,438
Growth (%) : 1
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 2,365
2022 Revenue in Millions : 2,473
Growth (%) : -4
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 4,428
2022 Revenue in Millions : 4,742
Growth (%) : -10
Main Therapeutic Indication : Anticoagulants
Currency : USD
2014 Revenue in Millions : 76.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Anticoagulants
Currency : USD
2015 Revenue in Millions : 1,847
2014 Revenue in Millions : 2,477
Growth (%) : 34%
LOOKING FOR A SUPPLIER?